Abstract
Acute coronary syndromes and, in paticular, ST – segment elevation myocardial infarction are the principle causes or mortality and morbidity in the industrialized countries. The manadgement of acute myocadial infarction is much debated in the literature; primary percutaneous coronary intervention is the treatment of choice. In the recent years there has been an increasing interest in the concept of adjunctive pharmacological therapy to improve outcomes in primary percutaneous coronary intervention. In the literature randomized trials of intravenous or more recently intracoronary injection of glycoprotein IIb/IIIa inhibitors have provided conflicting results with no definitive evidence for efficacy. The aim of the report is to review the evidence to our date on the role of intracoronary injection of abciximab during primary percutaneous intervention in the setting of acute myocardial infarction.
Keywords: STEMI, Acute coronary syndrome, adjuvant therapy, bleeding, GP IIb/IIIa inhibitors, in – stent restenosis, no – reflow phenomenon, percutaneous coronary intervention, platelet, thrombosis.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Volume: 11 Issue: 2
Author(s): Andrea Rognoni, Alessadro Lupi, Chiara Cavallino, Roberta Rosso, Alessia Veia, Sara Bacchini and Angelo Sante Bongo
Affiliation:
Keywords: STEMI, Acute coronary syndrome, adjuvant therapy, bleeding, GP IIb/IIIa inhibitors, in – stent restenosis, no – reflow phenomenon, percutaneous coronary intervention, platelet, thrombosis.
Abstract: Acute coronary syndromes and, in paticular, ST – segment elevation myocardial infarction are the principle causes or mortality and morbidity in the industrialized countries. The manadgement of acute myocadial infarction is much debated in the literature; primary percutaneous coronary intervention is the treatment of choice. In the recent years there has been an increasing interest in the concept of adjunctive pharmacological therapy to improve outcomes in primary percutaneous coronary intervention. In the literature randomized trials of intravenous or more recently intracoronary injection of glycoprotein IIb/IIIa inhibitors have provided conflicting results with no definitive evidence for efficacy. The aim of the report is to review the evidence to our date on the role of intracoronary injection of abciximab during primary percutaneous intervention in the setting of acute myocardial infarction.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessadro, Cavallino Chiara, Rosso Roberta, Veia Alessia, Bacchini Sara and Bongo Angelo Sante, Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020003
DOI https://dx.doi.org/10.2174/1871525711311020003 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design New Approaches for the Treatment of Chagas Disease
Current Drug Targets Artificial Intelligence as a Business Partner in Cardiovascular Precision Medicine: An Emerging Approach for Disease Detection and Treatment Optimization
Current Medicinal Chemistry Physiological Insights Derived from Mathematical Models of Respiration
Current Respiratory Medicine Reviews Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Visceral Adipose Tissue and Atherosclerosis
Current Vascular Pharmacology SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives
Current Medicinal Chemistry Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical Development
Current Medicinal Chemistry The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS)
Current Pharmaceutical Design Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews